In recent years, a revolutionary class of medications known as GLP-1 receptor agonists has transformed the landscape of medical weight management
During this window, the drug molecules are finding and binding to GLP-1 receptors scattered throughout your body
Editorial: Lifestyle interventions for childhood obesity: Broadening the reach and scope of impact
How often you administer your medication is dictated by a handful of critical, non-negotiable factors
It commonly involves prior authorization, limiting coverage to Food and Drug Administration-approved uses (type 2 diabetes and obesity, in the case of GLP-1s) and requiring proof of progress (i.e., ongoing weight loss) for continued coverage
This modification allows for a longer drug half-life, raising compliance as it enables once-weekly dosing